Lipella Pharmaceuticals Inc. SEC filings LIPO
Lipella Pharmaceuticals Inc. has 225 filings in SEC EDGAR's recent list, going back to Dec 9, 2005. Its latest annual report, Form 10-K, was filed on Mar 28, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Nov 14, 2025, covering the quarter ended Sep 30, 2025. The most recent current report (Form 8-K) was filed on Jul 15, 2026 (bankruptcy). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 1, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 9, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 9, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 7, 2025 | — |
| 4 | Insider transaction | Apr 7, 2025 | Apr 3, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 19, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 17, 2025 | — |
| 4 | Insider transaction | Mar 17, 2025 | Mar 13, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 11, 2025 | — |
| 4 | Insider transaction | Mar 11, 2025 | Mar 10, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 3, 2025 | — |
| 4 | Insider transaction | Mar 3, 2025 | Feb 28, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 10, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 10, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 30, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 30, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 23, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 23, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 17, 2025 | — |
| 4 | Insider transaction | Jan 17, 2025 | Jan 15, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 3, 2025 | — |
| 4 | Insider transaction | Jan 3, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 3, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 27, 2024 | — |
| 4 | Insider transaction | Dec 27, 2024 | Dec 23, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 17, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 17, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 19, 2024 | — |
| 4 | Insider transaction | May 15, 2024 | May 14, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | May 6, 2024 | — |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 19, 2024 | — |
| 4 | Insider transaction | Mar 15, 2024 | Mar 13, 2024 |
| 4 | Insider transaction | Mar 15, 2024 | Mar 13, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 15, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 15, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 6, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Mar 6, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 25, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jan 3, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 21, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 21, 2023 | — |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 4 | Insider transaction | Jun 21, 2023 | Jun 16, 2023 |
| 3 | Initial insider ownership | Jun 21, 2023 | Jun 17, 2023 |
| 3 | Initial insider ownership | Mar 30, 2023 | Mar 21, 2023 |
| SC 13G | Ownership over 5% (passive) | Mar 29, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Feb 9, 2023 | — |
| 3 | Initial insider ownership | Jan 3, 2023 | Dec 19, 2022 |
| 3 | Initial insider ownership | Jan 3, 2023 | Dec 19, 2022 |
| SC 13D | Ownership over 5% (active) | Dec 29, 2022 | — |
| SC 13D | Ownership over 5% (active) | Dec 29, 2022 | — |
| 4 | Insider transaction | Dec 27, 2022 | Dec 22, 2022 |
| 3 | Initial insider ownership | Dec 20, 2022 | Dec 19, 2022 |
| 3 | Initial insider ownership | Dec 20, 2022 | Dec 19, 2022 |
| 3 | Initial insider ownership | Dec 20, 2022 | Dec 19, 2022 |
| 3 | Initial insider ownership | Dec 20, 2022 | Dec 19, 2022 |
| 3 | Initial insider ownership | Dec 20, 2022 | Dec 19, 2022 |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIPO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pittsburgh, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1347242
- Former names
- LIPELLA PHARMACEUTICALS INC (until Sep 11, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.